temozolomide, within its licensed indications, is recommended as an option for the treatment of newly diagnosed glioblastoma multiforme in patients with a World Health Organization (WHO) performance status of 0 or 1
carmustine implants, within their licensed indications, are recommended as an option for the treatment of newly diagnosed high-grade glioma only for patients in whom 90% or more of the tumour has been resected
treatment with carmustine implants should be provided only within specialist centres
Notes:
WHO performance status classification categorises patients as:
0: able to carry out all normal activity without restriction
1: restricted in strenuous activity but ambulatory and able to carry out light work
2: ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
3: symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden
4: completely disabled; cannot carry out any self-care; totally confined to bed or chair
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page